Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today
announced that the name of the new company to be formed by the
planned combination of Mylan and Upjohn, a division of Pfizer, will
be Viatris (pronounced ‘viǝ-trīs).
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20191112005863/en/
Deriving its name from Latin, Viatris embodies the new company’s
goal of providing a path—“VIA”—to three—“TRIS”—core goals:
expanding access to medicines, leading by innovating to meet
patient needs, and being a trusted partner for the healthcare
community worldwide.
“We wanted a name that would differentiate our new company and
clearly explain how we will be a champion for global health,” said
Robert J. Coury, who will serve as Executive Chairman of the new
company, as previously announced. “We are creating a company unlike
any other – a company focused on building a more hopeful and
sustainable healthcare journey, empowering patients to live
healthier at every stage of life.”
“The name Viatris communicates the strength of our companies’
combined heritage and our shared goal to provide the
highest-quality medicines to the most patients possible,” said
Michael Goettler, Group President, Upjohn, who will serve as Chief
Executive Officer of Viatris, as previously announced. “We have an
opportunity to deliver better health, better care and better value
for patients and partners around the world.”
Formed through a combination of two highly complementary
businesses, Viatris will unite Upjohn’s strong leadership position
in China and emerging markets with Mylan’s significant presence in
the U.S. and Europe, allowing the new company to have a
meaningfully expanded geographic reach for Viatris’ broad product
portfolio and future pipeline.
It is expected that in the coming months, shareholders of Mylan
will vote on the proposed combination of Mylan and Upjohn. More
information regarding Viatris, including the company’s full
executive management team, board of directors, stock symbol, and
logo will be available at a later date.
Customers and patients will continue to be served by the Mylan
and Upjohn brands for the near future. The new name will be
effective upon closing of the combination, which is expected to
occur in mid-2020. The two companies will continue to operate as
independent, separate organizations until close.
For more information visit championforglobalhealth.com.
About Mylan
Mylan is a global pharmaceutical company committed to setting
new standards in healthcare. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 7,500 marketed products around the world,
including antiretroviral therapies on which approximately 40% of
people being treated for HIV/AIDS globally depend. We market our
products in more than 165 countries and territories. We are one of
the world's largest producers of active pharmaceutical ingredients.
Every member of our approximately 35,000-strong workforce is
dedicated to creating better health for a better world, one person
at a time. Learn more at Mylan.com. We routinely post information
that may be important to investors on our website at
investor.mylan.com.
About Upjohn
With over 130 years of experience in improving patient lives,
Pfizer Upjohn seeks to leverage our portfolio, global experience
and expertise to become the trusted partner of choice for all
stakeholders committed to improving patient health. We focus on
relieving the burden of non-communicable diseases with trusted,
quality medicines for every patient, everywhere, with the goal of
treating 225 million new patients by 2025. Upjohn brings together
20 of the industry’s most trusted brands — products such as
Lipitor®, Norvasc®, Lyrica® and Viagra® — with world-class medical,
manufacturing and commercial expertise in more than 120 countries.
Upjohn’s network of approximately 11,500 colleagues works together
to be fast, focused and flexible to ensure that patients around the
world access the healthcare they need.
About Pfizer: Breakthroughs That Change Patients’
Lives
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products. Our global portfolio includes medicines and vaccines as
well as many of the world's best-known consumer health care
products. Every day, Pfizer colleagues work across developed and
emerging markets to advance wellness, prevention, treatments and
cures that challenge the most feared diseases of our time.
Consistent with our responsibility as one of the world's premier
innovative biopharmaceutical companies, we collaborate with health
care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world.
For more than 150 years, we have worked to make a difference for
all who rely on us. We routinely post information that may be
important to investors on our website at www.Pfizer.com. In
addition, to learn more, please visit us on www.Pfizer.com and
follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube
and like us on Facebook at Facebook.com/Pfizer.
Forward-Looking Statements
This communication contains “forward-looking statements”. Such
forward-looking statements may include, without limitation,
statements about the proposed combination of Upjohn Inc. (“Newco”)
and Mylan N.V. (“Mylan”), which will immediately follow the
proposed separation of the Upjohn business (the “Upjohn Business”)
from Pfizer Inc. (“Pfizer”) (the “proposed transaction”), the
expected timetable for completing the proposed transaction, the
benefits and synergies of the proposed transaction, future
opportunities for the combined company and products and any other
statements regarding Pfizer’s, Mylan’s, the Upjohn Business’s or
the combined company’s future operations, financial or operating
results, capital allocation, dividend policy, debt ratio,
anticipated business levels, future earnings, planned activities,
anticipated growth, market opportunities, strategies, competitions,
and other expectations and targets for future periods.
Forward-looking statements may often be identified by the use of
words such as “will”, “may”, “could”, “should”, “would”, “project”,
“believe”, “anticipate”, “expect”, “plan”, “estimate”, “forecast”,
“potential”, “pipeline”, “intend”, “continue”, “target”, “seek” and
variations of these words or comparable words. Because
forward-looking statements inherently involve risks and
uncertainties, actual future results may differ materially from
those expressed or implied by such forward-looking statements.
Factors that could cause or contribute to such differences include,
but are not limited to: the parties’ ability to meet expectations
regarding the timing, completion and accounting and tax treatments
of the proposed transaction; changes in relevant tax and other
laws; the parties’ ability to consummate the proposed transaction;
the conditions to the completion of the proposed transaction,
including receipt of approval of Mylan’s shareholders, not being
satisfied or waived on the anticipated timeframe or at all; the
regulatory approvals required for the proposed transaction not
being obtained on the terms expected or on the anticipated schedule
or at all; inherent uncertainties involved in the estimates and
judgments used in the preparation of financial statements and the
providing of estimates of financial measures, in accordance with
accounting principles generally accepted in the United States of
America and related standards or on an adjusted basis; the
integration of Mylan and Newco being more difficult, time consuming
or costly than expected; Mylan’s, the Upjohn Business’s and the
combined company’s failure to achieve expected or targeted future
financial and operating performance and results; the possibility
that the combined company may be unable to achieve expected
benefits, synergies and operating efficiencies in connection with
the proposed transaction within the expected time frames or at all
or to successfully integrate Mylan and Newco; customer loss and
business disruption being greater than expected following the
proposed transaction; the retention of key employees being more
difficult following the proposed transaction; any regulatory, legal
or other impediments to Mylan’s, the Upjohn Business’s or the
combined company’s ability to bring new products to market,
including but not limited to where Mylan, the Upjohn Business or
the combined company uses its business judgment and decides to
manufacture, market and/or sell products, directly or through third
parties, notwithstanding the fact that allegations of patent
infringement(s) have not been finally resolved by the courts (i.e.,
an “at-risk launch”); success of clinical trials and Mylan’s, the
Upjohn Business’s or the combined company’s ability to execute on
new product opportunities; any changes in or difficulties with
Mylan’s, the Upjohn Business’s or the combined company’s
manufacturing facilities, including with respect to remediation and
restructuring activities, supply chain or inventory or the ability
to meet anticipated demand; the scope, timing and outcome of any
ongoing legal proceedings, including government investigations, and
the impact of any such proceedings on Mylan’s, the Upjohn
Business’s or the combined company’s consolidated financial
condition, results of operations and/or cash flows; Mylan’s, the
Upjohn Business’s and the combined company’s ability to protect
their respective intellectual property and preserve their
respective intellectual property rights; the effect of any changes
in customer and supplier relationships and customer purchasing
patterns; the ability to attract and retain key personnel; changes
in third-party relationships; actions and decisions of healthcare
and pharmaceutical regulators; the impacts of competition; changes
in the economic and financial conditions of the Upjohn Business or
the business of Mylan or the combined company; uncertainties
regarding future demand, pricing and reimbursement for our, the
Upjohn Business’s or the combined company’s products; and
uncertainties and matters beyond the control of management and
other factors described under “Risk Factors” in each of Pfizer’s
and Mylan’s Annual Reports on Form 10-K, Quarterly Reports on Form
10-Q and other filings with the Securities and Exchange Commission
(“SEC”). These risks, as well as other risks associated with Mylan,
the Upjohn Business, the combined company and the proposed
transaction are also more fully discussed in the Registration
Statement on Form S-4 which includes a proxy statement/prospectus
(the “Form S-4”), and Form 10 which includes an information
statement (the “Form 10”), each of which has been filed by Newco
with the SEC on October 25, 2019 and has not yet been declared
effective. You can access Pfizer’s, Mylan’s and Newco’s filings
with the SEC through the SEC website at www.sec.gov or through
Pfizer’s or Mylan’s website, as applicable, and Pfizer and Mylan
strongly encourage you to do so. Except as required by applicable
law, Pfizer, Mylan and Newco undertake no obligation to update any
statements herein for revisions or changes after the communications
on this website are made.
Additional Information and Where to Find It
This communication shall not constitute an offer to sell or the
solicitation of an offer to sell or the solicitation of an offer to
buy any securities, nor shall there be any sale of securities in
any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. No offer of securities
shall be made except by means of a prospectus meeting the
requirements of Section 10 of the Securities Act of 1933, as
amended. In connection with the proposed transaction, Newco and
Mylan have filed certain materials with the SEC, including, among
other materials, the Form S-4 and Form 10 filed by Newco. The
registration statements have not yet become effective. After the
Form S-4 is effective, a definitive proxy statement/prospectus will
be sent to the Mylan shareholders seeking approval of the proposed
transaction, and after the Form 10 is effective, a definitive
information statement will be made available to the Pfizer
stockholders relating to the proposed transaction. Newco and Mylan
intend to file additional relevant materials with the SEC in
connection with the proposed transaction, including a proxy
statement of Mylan in definitive form. INVESTORS AND SECURITY
HOLDERS ARE URGED TO READ DOCUMENTS FILED WITH THE SEC CAREFULLY
AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION ABOUT MYLAN, NEWCO AND THE PROPOSED TRANSACTION. The
documents relating to the proposed transaction (when they are
available) can be obtained free of charge from the SEC’s website at
www.sec.gov. These documents (when they are available) can also be
obtained free of charge from Mylan, upon written request to Mylan,
at (724) 514-1813 or investor.relations@mylan.com or from Pfizer on
Pfizer’s internet website at
https://investors.Pfizer.com/financials/sec-filings/default.aspx or
by contacting Pfizer’s Investor Relations Department at (212)
733-2323, as applicable.
Participants in the Solicitation
This communication is not a solicitation of a proxy from any
investor or security holder. However, Pfizer, Mylan, Newco and
certain of their respective directors and executive officers may be
deemed to be participants in the solicitation of proxies in
connection with the proposed transaction under the rules of the
SEC. Information about the directors and executive officers of
Pfizer may be found in its Annual Report on Form 10-K filed with
the SEC on February 28, 2019 and its definitive proxy statement and
additional proxy statement relating to its 2019 Annual Meeting
filed with the SEC on March 14, 2019 and on April 2, 2019,
respectively, and Current Report on Form 8-K filed with the SEC on
June 27, 2019. Information about the directors and executive
officers of Mylan may be found in its amended Annual Report on Form
10-K filed with the SEC on April 30, 2019, and its definitive proxy
statement relating to its 2019 Annual Meeting filed with the SEC on
May 24, 2019. Additional information regarding the interests of
these participants can also be found in the Form S-4 and will also
be included in the definitive proxy statement of Mylan in
connection with the proposed transaction when it becomes available.
These documents (when they are available) can be obtained free of
charge from the sources indicated above.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191112005863/en/
Mylan Media Relations: Christine Waller +1 (724) 514-1968
Communications@Mylan.com Mylan Investor Relations: Melissa
Trombetta +1 (724) 514-1813 Investorrelations@Mylan.com Pfizer
Media Relations: Patricia Kelly +1 (212) 733-3810
Patricia.Kelly@Pfizer.com Pfizer Investor Relations: Ryan
Crowe +1 (212) 733-8160 Ryan.Crowe@Pfizer.com
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Sep 2023 to Sep 2024